Clinical and bone marrow effects of α-interferon therapy in myelofibrosis with myeloid metaplasia.

被引：0
|
作者：
Tefferi, A [1 ]
Elliott, MA [1 ]
Yoon, SY [1 ]
Li, CY [1 ]
Mesa, RA [1 ]
Call, TG [1 ]
Dispenzieri, A [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3222
引用
收藏
页码：745A / 745A
页数：1
相关论文
共 50 条
  • [31] Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia
    Chou, JM
    Li, CY
    Tefferi, A
    LEUKEMIA RESEARCH, 2003, 27 (06) : 499 - 504
  • [32] Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia
    Ho, CL
    Arora, B
    Hoyer, JD
    Wellik, LE
    Mesa, RA
    Tefferi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (01) : 35 - 39
  • [33] Myelofibrosis with myeloid metaplasia: Targeted therapy
    Cairo, Mitchell S.
    BLOOD, 2007, 110 (01) : 2 - 3
  • [34] Thalidomide therapy for myelofibrosis with myeloid metaplasia
    Thomas, DA
    Giles, FJ
    Albitar, M
    Cortes, JE
    Verstovsek, S
    Faderl, S
    O'Brien, SM
    Garcia-Manero, G
    Keating, MJ
    Pierce, S
    Zeldis, J
    Kantarjian, HM
    CANCER, 2006, 106 (09) : 1974 - 1984
  • [35] Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Tefferi, Ayalew
    Cortes, Jorge
    Verstovsek, Srdan
    Mesa, Ruben A.
    Thomas, Deborah
    Lasho, Terra L.
    Hogan, William J.
    Litzow, Mark R.
    Allred, Jacob B.
    Jones, Dan
    Byrne, Catriona
    Zeldis, Jerome B.
    Ketterling, Rhett P.
    McClure, Rebecca F.
    Giles, Francis
    Kantarjian, Hagop M.
    BLOOD, 2006, 108 (04) : 1158 - 1164
  • [36] Experimental therapy in myelofibrosis with myeloid metaplasia
    Verstovsek, Srdan
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Tefferi, Ayalew
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (12) : 1555 - 1563
  • [37] Urinary markers of angiogenesis and their correlation with intramedullary manifestations of angiogenesis in myelofibrosis with myeloid metaplasia.
    Mesa, R
    Kay, N
    Li, CY
    Bone, N
    Gray, L
    Tefferi, A
    BLOOD, 2002, 100 (11) : 347B - 347B
  • [38] Lenalidomide (CC-5013) treatment for anemia associated with myelofibrosis with myeloid metaplasia.
    Tefferi, A
    Mesa, RA
    Hogan, WJ
    Shaw, TA
    Reyes, GE
    Allred, JB
    Ma, CX
    Dy, GK
    Wolanskyj, AR
    Litzow, ML
    Steensma, DP
    Call, TG
    McClure, RF
    BLOOD, 2005, 106 (11) : 726A - 726A
  • [39] Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia
    M. Merup
    J. Kutti
    G. Birgergård
    N. Mauritzson
    M. Björkholm
    B. Markevärn
    C. Malm
    J. Westin
    J. Palmblad
    J. Samuelsson
    Medical Oncology, 2002, 19 : 79 - 86
  • [40] Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia
    Merup, M
    Kutti, J
    Birgergård, G
    Mauritzson, N
    Björkholm, M
    Markevärn, B
    Malm, C
    Westin, J
    Palmblad, J
    Samuelsson, J
    MEDICAL ONCOLOGY, 2002, 19 (02) : 79 - 86
12345